Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03161665
Other study ID # UMCC 2015.140
Secondary ID HUM00107014
Status Completed
Phase N/A
First received May 18, 2017
Last updated November 29, 2017
Start date January 14, 2016
Est. completion date January 6, 2017

Study information

Verified date November 2017
Source University of Michigan Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hematopoietic cell transplantation (BMT), or commonly referred to as blood and marrow transplantation (BMT), is a potentially life-saving therapy for many malignant and non-malignant conditions. Despite advances over the past decade, which have led to improved outcomes, BMT remains an intense treatment modality often requiring prolonged inpatient--based care. While many patients endure the acute complications of the procedure, it is common for BMT patients and their caregivers to experience increased risk of financial and emotional burden, hospital readmission, and health service utilization. This highlights the importance of active involvement of BMT patients in their own health care (self--efficacy).

Given the intense nature of BMT, however, caregivers also play a critical role in the process and are a necessary component of proceeding with transplant. As such, caregiver activation on behalf of the patient plays a critical role in effective patient--caregiver-provider partnerships, which is increasingly recognized as the optimal model for health care delivery, particularly for those facing life--altering medical treatments. It is essential to develop effective strategies to enhance this partnership. Health information technology (IT)-mediated tools offer the potential to overcome constraints in health care delivery limited by provider time, complicated health information, and financial pressures. Significant gaps in knowledge exist on the use of health IT tools using low- cost and well- accepted delivery platforms in routine inpatient care, especially for high- risk or critically ill populations. We hypothesize that a tablet--based tool displaying personal health information could provide a platform to promote caregiver activation and enhance health communication.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date January 6, 2017
Est. primary completion date January 6, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Participants will be recruited by BMT RN Coordinators and physicians prior to patient admission to the BMT Unit. Caregiver (age 18 years or older) of any patient eligible to undergo autologous or allogeneic BMT and any patient (age 18 years or older) eligible to undergo autologous or allogeneic BMT will be recruited during the "Pre-Transplant Work-up" stage in the outpatient setting.

- CAREGIVER PARTICIPANTS: Caregiver (age 18 years or older) of a patient who will be hospitalized to undergo first-time autologous (self) or allogeneic (alternative donor) BMT in the University of Michigan Mott Children's Hospital BMT Unit

- PATIENT PARTICIPANTS: Patients (age 18 years or older) who will be hospitalized to undergo first-time autologous or allogeneic BMT will be given the opportunity to assent/consent and participate in the study. With his/her permission, the patient will also be provided with their own iPadĀ® BMT Roadmap information system to use. Qualitative interviews will be conducted in patients with their assent/consent.

- Ability to speak and read proficiently in English (the study's instruments have not been translated and validated in languages other than English)

- Willing and able to provide informed consent

- Willing to comply with study procedures and reporting requirements

Exclusion Criteria:

- Not willing and able to provide informed consent

- Not willing to comply with study procedures and reporting requirements

Study Design


Related Conditions & MeSH terms

  • Patients Undergoing Bone Marrow Transplant (BMT)

Intervention

Other:
BMT Roadmap
The BMT Roadmap is a health IT System that has been developed for use on the Apple iPad® to give the patient and caregivers easy access to test results, current treatment and contact information to hopefully increase active participation and engagement in transplant care.

Locations

Country Name City State
United States University of Michigan Health System Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
University of Michigan Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Caregivers Accrued Feasibility of the study will be determined by demonstrating that accruing at least 20% of caregivers from the BMT patient population is possible. 5 months